News in the field of SGLT2 inhibitors

Česká verzia

Authors: Zbynek Schroner
Authors place of work: LF UPJŠ a SchronerMED s. r. o., Košice
Published in the journal: Diab Obez 2021; 21(42): 86-89
Category: Reviews

Summary

Modern therapy of type 2 diabetes mellitus emphasis not only decrease of glycaemia, but also reduction of body weight and prevention of chronic microvascular and macrovascular complications with minamalization of risk of hypoglycemia. These requirements fulfill the newest class of oral antidiabetics – SGLT2 inhibitors. Cardioprotective and renoprotective effect of this class of drugs, was in recently published studies proven also in non-diabetics. In the field of SGLT2 inhibitors there are, in Slovakia new enlarged indications limitations for this group of drugs, also by clinical studies proven new therapeutic indications for SGLT2 inhibitors and also new guidelines for the heart failure, in which these drugs by EBM had important place.

Keywords:

SGLT2 inhibitors – new guidelines – new therapeutic indications

Zdroje

1. Rozhodnutie MZ SR zo dňa 15.7.2021: Číslo: S18122–2021- OKC-21147. Dostupné z WWW:<https://kategorizacia.mzsr.sk/Lieky/Common/Details/21147>.

2. Jardiance (empagliflozín). Súhrn charakteristických vlastností lieku. Dostupné z WWW:<https://ec.europa.eu/health/documents/community-register/2021/20210430151628/anx_151628_sk.pdf>.

3. Forxiga (dapagliflozín). Súhrn charakteristických vlastností lieku. Dostupné z WWW: <https://www.adc.sk/databazy/produkty/spc/forxiga-10-mg-filmom-obalene-tablety-931845.html>.

4. McMurray JJ, Solomon SD, Inzucchi SE et al. Dapagliflozin in patients with heart failure and reduced ejecion fraction. N Engl J Med 2019; 38(21): 1995–2008. Dostupné z DOI:<http://dx.doi.org/10.1056/NEJMoa1911303>.

5. Packer M, Anker SD, Butler G et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383(15): 1413–1424. Dostupné z DOI:<http://dx.doi.org/10.1056/NEJMoa2022190>.

6. Hiddo JL, Heerspink H, Bergur V et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383(15):1436–1446. Dostupné z DOI:<http://dx.doi.org/10.1056/NEJMoa2024816>.

7. Invokana (kanagflozín). Súhrn charakteristických vlastností lieku. Dostupné z WWW:<https://www.adc.sk/databazy/produkty/spc/invokana-100-mg-712244.html>.

8. Mahaffey KW, Jardine MJ, Bompoint S et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation 2019; 140(9): 739–750. Dostupné z DOI:<http://dx.doi.org/10.1161/CIRCULATIONAHA.119.042007> .

9. McDonagh TA, Metra M, Adamo M et al. [ESC Scientific Document Group]. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42(36): 3599–3726. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehab368>.

10. Anker SD, Butler J, Filippatos G et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385(16): 1451–1461. Dostupné z DOI:<http://dx.doi.org/10.1056/NEJMoa2107038> .